Skip to main content
. Author manuscript; available in PMC: 2021 Apr 1.
Published in final edited form as: Mol Imaging Biol. 2020 Apr;22(2):358–366. doi: 10.1007/s11307-019-01369-8

Fig. 6.

Fig. 6.

a Biodistribution data of [124I]IPAG in mouse bearing MCF-7 tumor xenografts (s.c.) at 24 and 48 h post administration. The corresponding blocking studies at 24 and 48 h with 100 fold excess of IPAG are also shown, which clearly demonstrated significantly reduced uptake in tumor, liver and salivary glands. b Biodistribution data of [124I]IPAG in mouse bearing MCF-7 tumor xenografts (s.c.) at 72 h post administration both at a tracer level and with a 3.5 fold excess of haloperidol (Haldol) block (n=3 for tumors).